141 citations
,
September 2016 in “European Journal of Dermatology” This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.
58 citations
,
September 2019 in “EMBO Molecular Medicine” This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.
31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.
19 citations
,
November 2018 in “Nutrients” This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.
11 citations
,
January 2022 in “Journal of Cancer” This article reviews the potential for low intensity ultrasound as an antidote for the peripheral cytotoxic side effects of taxane drugs in chemotherapy, presenting no new clinical results.
11 citations
,
August 2017 in “Supportive care in cancer” This study highlights the significant impact of eyebrow and eyelash loss during chemotherapy on women's quality of life, noting both emotional and physical challenges.
7 citations
,
March 2023 in “Journal of Investigative Dermatology” Low-intensity ultrasound may help protect hair follicles from chemotherapy-induced hair loss.
5 citations
,
June 2005 in “Journal of Clinical Oncology” This study found that paclitaxel poliglumex induces significantly less and milder alopecia compared with standard taxanes in ovarian and breast cancer patients.
3 citations
,
July 2018 in “Cureus” This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.
2 citations
,
March 2021 in “Cutis” This article highlights that permanent chemotherapy-induced alopecia can occur and is more commonly associated with taxane therapy, advising awareness among patients and clinicians.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study provides ex vivo proof-of-principle that low-intensity ultrasound may protect human hair follicles from paclitaxel-induced damage, potentially reducing chemotherapy-related alopecia.
November 2024 in “Journal of Investigative Dermatology” Paclitaxel chemotherapy causes premature aging and damage to hair follicles, potentially leading to permanent hair loss.
July 2024 in “Journal of Investigative Dermatology” Taxane chemotherapy can cause permanent hair loss by damaging hair follicles and altering their DNA.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
This review discusses various strategies to mitigate taxane-induced alopecia in cancer treatment, highlighting the potential of low-intensity ultrasound to reverse hair follicle damage by disrupting taxane-stabilized microtubules.
1 citations
,
June 2025 in “Supportive Care in Cancer” This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.
5 citations
,
January 2024 in “BMC Cancer” In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.
December 2025 in “Drug Design Development and Therapy” This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.
9 citations
,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
May 2018 in “Journal of Clinical Oncology” This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.
724 citations
,
April 2004 in “Lancet Oncology” This review summarizes the use and neonatal outcomes of chemotherapy during pregnancy, noting its potential for safe use in the second and third trimesters, and reports no new clinical results.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
55 citations
,
November 2004 in “Expert opinion on drug safety” This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.
43 citations
,
March 2019 in “JAMA Dermatology” This study found that persistent chemotherapy-induced alopecia is often more severe and diffuse than alopecia from endocrine therapy, with both conditions negatively impacting patients' emotional wellbeing, and moderate to significant improvement was observed with dermatologic therapy.
25 citations
,
March 2018 in “Journal of oncology practice” This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.
6 citations
,
April 2022 in “The Breast” This study found that scalp cooling significantly reduced chemotherapy-induced hair loss in breast cancer patients, especially those receiving taxane monotherapy, but did not significantly affect hair regrowth after chemotherapy.
4 citations
,
March 2024 in “Journal of the American Academy of Dermatology” Scalp cooling therapy is costly and often not covered by insurance, limiting access for low-income patients.
3 citations
,
June 2011 in “Korean Journal of Clinical Oncology” This article discusses chemotherapy-induced alopecia and its significant psychological impact on cancer patients, noting that some may even refuse treatment due to fear of hair loss.
2 citations
,
May 2016 in “Journal of Clinical Oncology” This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.
2 citations
,
June 2024 in “JAAD reviews.” In this review, researchers summarize drugs associated with scarring or permanent hair loss, notably after chemotherapy and tyrosine kinase inhibitor treatments, emphasizing the need for stronger evidence and long-term follow-up studies, as current findings are mostly from case reports.